|Articles|May 18, 2016
CDISC and TransCelerate Announce New Standard for Breast Cancer
CDISC and TransCelerate announce new Therapuetic Area Standard for Breast Cancer, which allows for data to be shared among industry professionals.
Advertisement
CDISC and TransCelerate announce the availability of a new CDISC Therapeutic Area Standard for Breast Cancer. This standard has the ability to streamline the way clinical research is conducted so that data can be shared among clinicians, researchers and regulators worldwide. Read the full release here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
How Sponsors Can Modernize Tools to Support PhysiciansSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
2
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
3
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
4
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
